Drug Discovery with Dynamic Goal-aware Fragments

Read original: arXiv:2310.00841 - Published 5/31/2024 by Seul Lee, Seanie Lee, Kenji Kawaguchi, Sung Ju Hwang

🚀

Overview

Discusses a new molecular generative framework called GEAM for drug discovery
GEAM consists of three modules: goal-aware fragment extraction, fragment assembly, and fragment modification
Aims to address limitations of existing fragment-based drug discovery methods

Plain English Explanation

GEAM is a new framework for generating potential drug molecules. It works by breaking down existing drug molecules into smaller fragments, then reassembling and modifying those fragments in strategic ways to create new drug candidates.

The key innovation of GEAM is that it focuses on extracting fragments that are specifically relevant to the desired properties of the target drug, rather than just using heuristic rules or random sampling. This "goal-aware" fragment extraction helps ensure the new molecules have a higher chance of exhibiting the target properties.

GEAM also has the ability to explore beyond its initial fragment vocabulary, discovering new fragments that may be useful. And it can dynamically update its fragment library as new promising fragments are found during the generation process.

By combining these targeted fragment extraction, assembly, and modification capabilities, GEAM aims to efficiently navigate the vast chemical space to discover effective drug candidates for various applications.

Technical Explanation

The GEAM framework consists of three main modules:

Fragment Extraction: This module identifies important fragments that contribute to the desired target properties, using the information bottleneck principle. This allows GEAM to construct an effective "goal-aware" fragment vocabulary.
Fragment Assembly: This module is responsible for assembling the extracted fragments into new molecular structures.
Fragment Modification: This module can explore beyond the initial fragment vocabulary, discovering new promising fragments. The exploration is further enhanced through dynamic updates to the goal-aware fragment library.

The three modules work together in a generative cycle to efficiently explore the chemical space and discover drug candidates. GEAM is evaluated on various drug discovery tasks, and the experiments demonstrate its effectiveness at generating molecules with the target properties.

Critical Analysis

The GEAM framework addresses some key limitations of existing fragment-based drug discovery methods. By focusing on extracting goal-aware fragments and dynamically updating the fragment vocabulary, it aims to more effectively navigate the vast chemical space.

However, the paper does not provide a deep analysis of the limitations of the goal-aware fragment extraction approach or discuss potential edge cases where it may struggle. Additionally, the long-term stability and generalizability of the goal-aware fragment vocabulary updates are not extensively evaluated.

Further research could explore ways to make the goal-aware fragment extraction more robust and adaptable, as well as investigate the scalability and computational efficiency of the GEAM framework as the molecular complexity and target property diversity increases.

Conclusion

GEAM presents a promising new approach to fragment-based drug discovery, leveraging goal-aware fragment extraction, assembly, and modification to more effectively navigate the chemical space and generate drug candidates. By focusing on extracting fragments relevant to the target properties and dynamically updating the fragment vocabulary, GEAM aims to overcome limitations of existing fragment-based methods. Further research is needed to fully assess the long-term robustness and scalability of this framework, but the core ideas show potential for advancing the field of computational drug discovery.

This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!

Follow @aimodelsfyi on 𝕏 →

Related Papers

🚀

Drug Discovery with Dynamic Goal-aware Fragments

Seul Lee, Seanie Lee, Kenji Kawaguchi, Sung Ju Hwang

Fragment-based drug discovery is an effective strategy for discovering drug candidates in the vast chemical space, and has been widely employed in molecular generative models. However, many existing fragment extraction methods in such models do not take the target chemical properties into account or rely on heuristic rules. Additionally, the existing fragment-based generative models cannot update the fragment vocabulary with goal-aware fragments newly discovered during the generation. To this end, we propose a molecular generative framework for drug discovery, named Goal-aware fragment Extraction, Assembly, and Modification (GEAM). GEAM consists of three modules, each responsible for goal-aware fragment extraction, fragment assembly, and fragment modification. The fragment extraction module identifies important fragments contributing to the desired target properties with the information bottleneck principle, thereby constructing an effective goal-aware fragment vocabulary. Moreover, GEAM can explore beyond the initial vocabulary with the fragment modification module, and the exploration is further enhanced through the dynamic goal-aware vocabulary update. We experimentally demonstrate that GEAM effectively discovers drug candidates through the generative cycle of the three modules in various drug discovery tasks. Our code is available at https://github.com/SeulLee05/GEAM.

5/31/2024

TAGMol: Target-Aware Gradient-guided Molecule Generation

Vineeth Dorna, D. Subhalingam, Keshav Kolluru, Shreshth Tuli, Mrityunjay Singh, Saurabh Singal, N. M. Anoop Krishnan, Sayan Ranu

3D generative models have shown significant promise in structure-based drug design (SBDD), particularly in discovering ligands tailored to specific target binding sites. Existing algorithms often focus primarily on ligand-target binding, characterized by binding affinity. Moreover, models trained solely on target-ligand distribution may fall short in addressing the broader objectives of drug discovery, such as the development of novel ligands with desired properties like drug-likeness, and synthesizability, underscoring the multifaceted nature of the drug design process. To overcome these challenges, we decouple the problem into molecular generation and property prediction. The latter synergistically guides the diffusion sampling process, facilitating guided diffusion and resulting in the creation of meaningful molecules with the desired properties. We call this guided molecular generation process as TAGMol. Through experiments on benchmark datasets, TAGMol demonstrates superior performance compared to state-of-the-art baselines, achieving a 22% improvement in average Vina Score and yielding favorable outcomes in essential auxiliary properties. This establishes TAGMol as a comprehensive framework for drug generation.

6/5/2024

🛸

A Review on Fragment-based De Novo 2D Molecule Generation

Sergei Voloboev

In the field of computational molecule generation, an essential task in the discovery of new chemical compounds, fragment-based deep generative models are a leading approach, consistently achieving state-of-the-art results in molecular design benchmarks as of 2023. We present a detailed comparative assessment of their architectures, highlighting their unique approaches to molecular fragmentation and generative modeling. This review also includes comparisons of output quality, generation speed, and the current limitations of specific models. We also highlight promising avenues for future research that could bridge fragment-based models to real-world applications.

5/10/2024

Cell Morphology-Guided Small Molecule Generation with GFlowNets

Stephen Zhewen Lu, Ziqing Lu, Ehsan Hajiramezanali, Tommaso Biancalani, Yoshua Bengio, Gabriele Scalia, Micha{l} Koziarski

High-content phenotypic screening, including high-content imaging (HCI), has gained popularity in the last few years for its ability to characterize novel therapeutics without prior knowledge of the protein target. When combined with deep learning techniques to predict and represent molecular-phenotype interactions, these advancements hold the potential to significantly accelerate and enhance drug discovery applications. This work focuses on the novel task of HCI-guided molecular design. Generative models for molecule design could be guided by HCI data, for example with a supervised model that links molecules to phenotypes of interest as a reward function. However, limited labeled data, combined with the high-dimensional readouts, can make training these methods challenging and impractical. We consider an alternative approach in which we leverage an unsupervised multimodal joint embedding to define a latent similarity as a reward for GFlowNets. The proposed model learns to generate new molecules that could produce phenotypic effects similar to those of the given image target, without relying on pre-annotated phenotypic labels. We demonstrate that the proposed method generates molecules with high morphological and structural similarity to the target, increasing the likelihood of similar biological activity, as confirmed by an independent oracle model.

8/12/2024